HIV Clinical Trials in Rochester, New York

3 studies are recruiting for hiv in Rochester, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Phase 1 Study of CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy Adults

    This Phase 1 study will evaluate the safety, tolerability, and immune responses of investigational CH505 HIV vaccine regimens in adults in overall good health without HIV. Participants will receive CH505 protein nanoparticle vaccines (DV901-NP) formulated with the investigational adjuvant ACU-026-0…

    Stage
    Phase 1
    Ages
    18 to 55
    Site
    University of Rochester Vaccines to Prevent HIV Infection CRS Site# 31467, Rochester, New York
    Locations
    8 in total
    Run by
    National Institute of Allergy and Infectious Diseases (NIAID)

    See if you can join NCT07757802 on ClinicalTrials.gov

  2. A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies

    This phase 1 study will evaluate the safety, tolerability, and immune responses of two experimental mRNA HIV vaccines in adults living with HIV who are in overall good health. The study will enroll about 42 participants at multiple study sites. Researchers will assess whether these vaccines can sta…

    Stage
    Phase 1
    Ages
    18 to 60
    Site
    University of Rochester Vaccines to Prevent HIV Infection CRS (Site#: 31467), Rochester, New York
    Locations
    16 in total
    Run by
    National Institute of Allergy and Infectious Diseases (NIAID)

    See if you can join NCT07569029 on ClinicalTrials.gov

  3. Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA in Adult Participants Without HIV

    This is a phase 1, multicenter, open-label, dose escalation, first-in-human (FIH) trial to evaluate the safety and immunogenicity of DV201P-RNA and DV202B1-RNA, immunogens designed to induce HIV-1 envelope (Env) V2 apex-specific broadly neutralizing antibodies (V2 apex bnAbs). Both vaccines consist…

    Stage
    Phase 1
    Ages
    18 to 55
    Site
    University of Rochester Vaccines to Prevent HIV Infection CRS (Site ID 31467), Rochester, New York
    Locations
    7 in total
    Run by
    National Institute of Allergy and Infectious Diseases (NIAID)

    See if you can join NCT07390474 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.